Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Sridharan K, Fiala O, Sivaramakrishnan G, Matrana MR, Büttner T, Kucharz J, Molina Cerrillo J, Giannatempo P, Myint ZW, Gómez de Liaño A, Pirshtuk A, Mota A, Kanesvaran R, Ürün Y, Angel M, Soule T, Massari F, Bellmunt J, Gupta S, Santoni M

Open source

DOI: 10.1080/14712598.2026.2727098
Published: 2026 Sep 3
Container: Expert opinion on biological therapy
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14712598.2026.2727098,
  title = {Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.},
  author = {Sridharan K and Fiala O and Sivaramakrishnan G and Matrana MR and Büttner T and Kucharz J and Molina Cerrillo J and Giannatempo P and Myint ZW and Gómez de Liaño A and Pirshtuk A and Mota A and Kanesvaran R and Ürün Y and Angel M and Soule T and Massari F and Bellmunt J and Gupta S and Santoni M},
  year = {2026},
  journal = {Expert opinion on biological therapy},
  doi = {10.1080/14712598.2026.2727098},
  url = {https://doi.org/10.1080/14712598.2026.2727098}
}

RIS

TY  - JOUR
TI  - Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.
AU  - Sridharan K
AU  - Fiala O
AU  - Sivaramakrishnan G
AU  - Matrana MR
AU  - Büttner T
AU  - Kucharz J
AU  - Molina Cerrillo J
AU  - Giannatempo P
AU  - Myint ZW
AU  - Gómez de Liaño A
AU  - Pirshtuk A
AU  - Mota A
AU  - Kanesvaran R
AU  - Ürün Y
AU  - Angel M
AU  - Soule T
AU  - Massari F
AU  - Bellmunt J
AU  - Gupta S
AU  - Santoni M
PY  - 2026
JO  - Expert opinion on biological therapy
DO  - 10.1080/14712598.2026.2727098
UR  - https://doi.org/10.1080/14712598.2026.2727098
ER  -

APA

K, S., O, F., G, S., MR, M., T, B., J, K., J, M. C., P, G., ZW, M., A, G. D. L., A, P., A, M., R, K., Y, Ü., M, A., T, S., F, M., J, B., S, G., & M, S. (2026). Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.. Expert opinion on biological therapy. https://doi.org/10.1080/14712598.2026.2727098

Source records

pubmed · retrieved 2026-09-25T21:08:17.213Z
europe-pmc · retrieved 2026-09-25T21:08:17.224Z